| 2025-04-30 12:00:00 |
Ipsen S.a. - Formalities For Making Available And Consulting Preparatory Documents To The 2025 Annual General Meeting
Information relating to the holding of the combined shareholders’ meeting of 21 may 2025 of ipsen s.a. formalities for making available and consulting preparatory documents to the meeting paris, france, 30 april 2025 - ipsen (euronext: ipn; adr: ipsey) announced today that the shareholders of the company are invited to participate in the combined shareholders’ meeting of ipsen (euronext: ipn; adr: ipsey) to be held on wednesday 21 may 2025 at 3:00 p.m. |
| 2024-10-03 06:30:00 |
Eton Pharmaceuticals, Inc To Acquire Increlex® (mecasermin Injection) From Ipsen
Aligns with eton’s mission to develop and distribute medicines that have a life changing impact for patients with ultra-rare conditions |
| 2024-09-23 01:30:00 |
Genfit: Ipsen’s Iqirvo® (elafibranor) Receives Eu Approval As A First-in-class Treatment For Primary Biliary Cholangitis Following U.s. Fda Accelerated Approval
Lille (france), cambridge (massachusetts, united states), zurich (switzerland), september 23, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that the european commission has conditionally approved iqirvo®1 (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca or as a monotherapy in patients unable to tolerate udca. this follows the positive opinion issued by the committee for medicinal products for human use (chmp) of the european medicines agency (ema) on july 26, 2024 and the u.s. fda accelerated approval on june, 10, 2024 . |
| 2024-08-29 14:14:00 |
Ipsen’s Iqirvo Shows Strong Start In Primary Biliary Cholangitis, Now Faces Rivalry From Gilead’s Livdelzi
Prior to the approvals and launches of iqirvo and livdelzi, us gastroenterologists notably favored the second to market livdelzi as their preferred asset. prior to the approvals and launches of iqirvo and livdelzi, us gastroenterologists notably favored the second to market livdelzi as their preferred asset. |
| 2024-07-26 07:45:00 |
Genfit: Positive Opinion From Ema Committee For Ipsen’s Iqirvo® (elafibranor) In Primary Biliary Cholangitis
Lille (france), cambridge (massachusetts, united states), zurich (switzerland), july 26, 2024 - genfit (nasdaq and euronext: gnft), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the committee for medicinal products for human use (chmp) of the european medicines agency’s (ema) for ipsen’s iqirvo® (elafibranor) for the treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca or as a monotherapy in patients unable to tolerate udca. |
| 2024-07-25 08:18:00 |
SXBzZW4gUy5hLiBQdWJs aXNoZXMgSXRzIDIwMjQg SGFsZi15ZWFyIFJlcG9y dCAoaGFsZi15ZWFyIEVu ZGVkIDMwIEp1bmUgMjAy NCk=
SXBzZW4gcy5hLiBwdWJs aXNoZXMgaXRzIDIwMjQg aGFsZi15ZWFyIHJlcG9y dCAoaGFsZi15ZWFyIGVu ZGVkIDMwIGp1bmUgMjAy NCkgYXR0YWNobWVudCAy MDI0IGlwc2VuIGhhbGYt eWVhciBmaW5hbmNpYWwg cmVwb3J0
|
| 2024-07-25 00:58:00 |
SXBzZW4gQW5kIERheSBP bmUgRW50ZXIgSW50byBF eGNsdXNpdmUgRXgtdS5z LiBMaWNlbnNpbmcgQWdy ZWVtZW50IFRvIENvbW1l cmNpYWxpemUgVG92b3Jh ZmVuaWIgRm9yIFRoZSBN b3N0IENvbW1vbiBDaGls ZGhvb2QgQnJhaW4gVHVt b3I=
UGFyaXMsIGZyYW5jZSwg YW5kIGJyaXNiYW5lLCBj YWxpZm9ybmlhIHUucy4s IDI1IGp1bHkgMjAyNCAt IGlwc2VuIChldXJvbmV4 dDogaXBuOyBhZHI6IGlw c2V5KSBhbmQgZGF5IG9u ZSBiaW9waGFybWFjZXV0 aWNhbHMgKG5hc2RhcTog ZGF3bikgKGRheSBvbmUp LCBhbm5vdW5jZWQgdG9k YXkgYSBuZXcgZ2xvYmFs IHBhcnRuZXJzaGlwIG91 dHNpZGUgdGhlIHUucy4g Zm9yIHRvdm9yYWZlbmli LCBhbiBvcmFsLCBvbmNl LXdlZWtseSwgdHlwZSBp aSByYWYgaW5oaWJpdG9y IGZvciBwZWRpYXRyaWMg bG93IGdyYWRlIGdsaW9t YSAocGxnZyksIHRoZSBt b3N0IGNvbW1vbiBmb3Jt IG9mIGNoaWxkaG9vZCBi cmFpbiBjYW5jZXIsIGkg YW5kIGFueSBmdXR1cmUg aW5kaWNhdGlvbnMgZGV2 ZWxvcGVkIGJ5IGRheSBv bmUu
|
| 2024-06-10 17:22:00 |
R2VuZml0OiBIaXN0b3Jp YyBNaWxlc3RvbmUgQWNo aWV2ZWQgV2l0aCBVLnMu IEZkYSBBY2NlbGVyYXRl ZCBBcHByb3ZhbCBPZiBJ cHNlbuKAmXMgSXFpcnZv wq4gRm9yIFByaW1hcnkg QmlsaWFyeSBDaG9sYW5n aXRpcw==
TGlsbGUgKGZyYW5jZSks IGNhbWJyaWRnZSAobWFz c2FjaHVzZXR0cywgdW5p dGVkIHN0YXRlcyksIHp1 cmljaCAoc3dpdHplcmxh bmQpLCBqdW5lIDEwLCAy MDI0IC0gZ2VuZml0IChu YXNkYXEgYW5kIGV1cm9u ZXh0OiBnbmZ0KSwgYSBs YXRlLXN0YWdlIGJpb3Bo YXJtYWNldXRpY2FsIGNv bXBhbnkgZGVkaWNhdGVk IHRvIGltcHJvdmluZyB0 aGUgbGl2ZXMgb2YgcGF0 aWVudHMgd2l0aCByYXJl IGFuZCBsaWZlLXRocmVh dGVuaW5nIGxpdmVyIGRp c2Vhc2VzLCB0b2RheSBh bm5vdW5jZWQgdGhlIGFj aGlldmVtZW50IG9mIGEg aGlzdG9yaWMgY29ycG9y YXRlIG1pbGVzdG9uZTog dGhlIHUucy4gZm9vZCBh bmQgZHJ1ZyBhZG1pbmlz dHJhdGlvbiAoZmRhKSBh Y2NlbGVyYXRlZCBhcHBy b3ZhbCBvZiBpcWlydm8x IChlbGFmaWJyYW5vciky IDgwIG1nIHRhYmxldHMg 4oCTIGFzIHVudmVpbGVk IHRvZGF5IGJ5IGlwc2Vu IChldXJvbmV4dDogaXBu OyBhZHI6IGlwc2V5KSDi gJMgYXMgYSBmaXJzdC1p bi1jbGFzcyB0cmVhdG1l bnQgZm9yIHBiYyBpbiBj b21iaW5hdGlvbiB3aXRo IHVyc29kZW94eWNob2xp YyBhY2lkICh1ZGNhKSBp biBhZHVsdHMgd2l0aCBh biBpbmFkZXF1YXRlIHJl c3BvbnNlIHRvIHVkY2Es IG9yIGFzIG1vbm90aGVy YXB5IGluIHBhdGllbnRz IHVuYWJsZSB0byB0b2xl cmF0ZSB1ZGNhLg==
|
| 2024-05-28 12:00:00 |
QW5udWFsIEdlbmVyYWwg TWVldGluZyBPZiBJcHNl biBTLmEuIEhlbGQgT24g MjggTWF5IDIwMjQ=
UGFyaXMsIGZyYW5jZSwg MjggbWF5IDIwMjQgLSB0 aGUgYW5udWFsIGdlbmVy YWwgbWVldGluZyBvZiBp cHNlbiBzLmEuIChldXJv bmV4dDogaXBuOyBhZHI6 IGlwc2V5KSB3YXMgaGVs ZCB0b2RheSBhdCB0aGUg c2Fsb25zIGRlIGzigJlo w5R0ZWwgZGVzIGFydHMg ZXQgbcOJdGllcnMsIDkg YmlzLCBhdmVudWUgZOKA mWnDiW5hLCA3NTExNiBw YXJpcyAoZnJhbmNlKSwg dW5kZXIgdGhlIGNoYWly bWFuc2hpcCBvZiBtci4g bWFyYyBkZSBnYXJpZGVs LCBjaGFpcm1hbiBvZiB0 aGUgYm9hcmQgb2YgZGly ZWN0b3JzLCBhbmQgaW4g dGhlIHByZXNlbmNlIG9m IHRoZSBtZW1iZXJzIG9m IHRoZSBib2FyZCBvZiBk aXJlY3RvcnMgYW5kIHRo ZSBncm91cOKAmXMgZXhl Y3V0aXZlIGxlYWRlcnNo aXAgdGVhbS4=
|
| 2024-05-28 01:00:00 |
RGVzY3JpcHRpb24gT2Yg VGhlIFJlZ3VsYXRvcnkg RnJhbWV3b3JrIE9mIFRo ZSBTaGFyZSBSZXB1cmNo YXNlIFByb2dyYW0gUHJv cG9zZWQgQnkgVGhlIEJv YXJkIE9mIERpcmVjdG9y cyBUbyBCZSBBcHByb3Zl ZCBBdCBJcHNlbiBTLmEu 4oCZcyBBbm51YWwgR2Vu ZXJhbCBNZWV0aW5nIE9u IDI4IE1heSAyMDI0
UGFyaXMsIGZyYW5jZSwg MjggbWF5IDIwMjQgLcKg aW4gYWNjb3JkYW5jZSB3 aXRoIHRoZSBwcm92aXNp b25zIG9mIGFydGljbGUg bC4yMi0xMC02MiBldCBz ZXEuIG9mIHRoZSBmcmVu Y2ggY29tbWVyY2lhbCBj b2RlLCB0aGUgZXVyb3Bl YW4gcmVndWxhdGlvbiAo ZXUpIG5vIDU5Ni8yMDE0 IG9mIHRoZSBldXJvcGVh biBwYXJsaWFtZW50IGFu ZCBvZiB0aGUgY291bmNp bCBvZiAxNiBhcHJpbCAy MDE0LCB0aGUgZGVsZWdh dGVkIHJlZ3VsYXRpb24g bm8gMjAxNi8xMDUyIG9m IDggbWFyY2ggMjAxNiwg YW5kIHRoZSBnZW5lcmFs IHJlZ3VsYXRpb24gb2Yg dGhlIGZyZW5jaCBhdXRv cml0w4kgZGVzIG1hcmNo w4lzIGZpbmFuY2llcnMg KGFtZiksIHRoZSBwcmVz ZW50IGRlc2NyaXB0aW9u IGFpbXMgdG8gZGVzY3Jp YmUgdGhlIG9iamVjdGl2 ZXMgYW5kIGNoYXJhY3Rl cmlzdGljcyBvZiB0aGUg cmVwdXJjaGFzZSBieSB0 aGUgY29tcGFueSBvZiBp dHMgb3duIHNoYXJlcywg dGhhdCBpdCBjb3VsZCBp biB0aGVvcnkgaW1wbGVt ZW50LiB0aGlzIHJlcHVy Y2hhc2UgaXMgcHJvcG9z ZWQgdG8gdGhlIGF1dGhv cml6YXRpb24gb2YgdG9k YXnigJlzICgyOCBtYXkg MjAyNCkgYW5udWFsIGdl bmVyYWwgbWVldGluZyBp biBpdHMgMTV0aCByZXNv bHV0aW9uLiB0aGUgcHJl bGltaW5hcnkgbm90aWNl IG9mIG1lZXRpbmcsIGlu Y2x1ZGluZyB0aGUgYWdl bmRhIGFuZCB0aGUgZHJh ZnQgcmVzb2x1dGlvbnMs IGhhcyBiZWVuIHB1Ymxp c2hlZCBpbiB0aGUgYnVs bGV0aW4gZGVzIGFubm9u Y2VzIGzDiWdhbGVzIG9i bGlnYXRvaXJlcyAoYmFs bykgb24gMTcgYXByaWwg MjAyNCBhbmQgdGhlIG5v dGljZSBvZiBtZWV0aW5n IGluIHRoZSBiYWxvIG9u IDYgbWF5IDIwMjQu
|
| 2024-05-07 08:55:00 |
SXBzZW4gUy5hLiAtIEZv cm1hbGl0aWVzIEZvciBN YWtpbmcgQXZhaWxhYmxl IEFuZCBDb25zdWx0aW5n IFByZXBhcmF0b3J5IERv Y3VtZW50cyBUbyBUaGUg MjAyNCBBbm51YWwgR2Vu ZXJhbCBNZWV0aW5n
SW5mb3JtYXRpb24gcmVs YXRpbmcgdG8gdGhlIGhv bGRpbmcgb2YgdGhlIGNv bWJpbmVkIHNoYXJlaG9s ZGVyc+KAmSBtZWV0aW5n IG9mIDI4IG1heSAyMDI0 IG9mIGlwc2VuIHMuYS4g Zm9ybWFsaXRpZXMgZm9y IG1ha2luZyBhdmFpbGFi bGUgYW5kIGNvbnN1bHRp bmcgcHJlcGFyYXRvcnkg ZG9jdW1lbnRzIHRvIHRo ZSBtZWV0aW5nIGJvdWxv Z25lLWJpbGxhbmNvdXJ0 LCBmcmFuY2UsIDcgbWF5 IDIwMjQgLSB0aGUgc2hh cmVob2xkZXJzIG9mIHRo ZSBjb21wYW55IGFyZSBp bnZpdGVkIHRvIHBhcnRp Y2lwYXRlIGluIHRoZSBj b21iaW5lZCBzaGFyZWhv bGRlcnPigJkgbWVldGlu ZyBvZiBpcHNlbiAoZXVy b25leHQ6IGlwbjsgYWRy OiBpcHNleSkgdG8gYmUg aGVsZCBvbiB0dWVzZGF5 IDI4wqBtYXkgMjAyNCBh dCAzOjAwIHAubS4=
|
| 2024-02-15 04:00:00 |
SXBzZW4gUy5hLiBQdWJs aXNoZXMgSXRzIDIwMjMg Q29uc29saWRhdGVkIEZp bmFuY2lhbCBTdGF0ZW1l bnRz
SXBzZW4gcy5hLiAtIDIw MjMgY29uc29saWRhdGVk IGZpbmFuY2lhbCBzdGF0 ZW1lbnRzIGF0dGFjaG1l bnQgaXBzZW4gLSAyMDIz IGNvbnNvbGlkYXRlZCBm aW5hbmNpYWwgc3RhdGVt ZW50cw==
|
| 2023-08-16 15:32:00 |
VXMgRmRhIEFwcHJvdmVz IElwc2Vu4oCZcyBTb2hv bm9zdG0gKHBhbG92YXJv dGVuZSkgQ2Fwc3VsZXMs IFRoZSBGaXJzdCBBbmQg T25seSBUcmVhdG1lbnQg Rm9yIFBlb3BsZSBXaXRo IEZpYnJvZHlzcGxhc2lh IE9zc2lmaWNhbnMgUHJv Z3Jlc3NpdmE=
UGFyaXMsIGZyYW5jZSwg MTYgYXVndXN0IDIwMjMg 4oCTIGlwc2VuIChldXJv bmV4dDogaXBuOyBhZHI6 IGlwc2V5KSBhbm5vdW5j ZWQgdG9kYXkgYXBwcm92 YWwgYnkgdGhlIHUucy4g Zm9vZCBhbmQgZHJ1ZyBh ZG1pbmlzdHJhdGlvbiAo ZmRhKSBvZiBzb2hvbm9z 4oSiIChwYWxvdmFyb3Rl bmUpIGNhcHN1bGVzIGFz IGEgcmV0aW5vaWQgaW5k aWNhdGVkIGZvciB0aGUg cmVkdWN0aW9uIGluIHZv bHVtZSBvZiBuZXcgaGV0 ZXJvdG9waWMgb3NzaWZp Y2F0aW9uIGluIGFkdWx0 cyBhbmQgcGVkaWF0cmlj IHBhdGllbnRzIGFnZWQg OCB5ZWFycyBhbmQgb2xk ZXIgZm9yIGZlbWFsZXMg YW5kIDEwIHllYXJzIGFu ZCBvbGRlciBmb3IgbWFs ZXMgd2l0aCBmaWJyb2R5 c3BsYXNpYSBvc3NpZmlj YW5zIHByb2dyZXNzaXZh IChmb3ApLg==
|
| 2023-07-27 12:06:00 |
SXBzZW4gUy5hLiBQdWJs aXNoZXMgSXRzIDIwMjMg SGFsZi15ZWFyIEZpbmFu Y2lhbCBSZXBvcnQ=
SXBzZW4gcy5hLiBwdWJs aXNoZXMgaXRzIDIwMjMg aGFsZi15ZWFyIGZpbmFu Y2lhbCByZXBvcnQgYXR0 YWNobWVudCAyMDIzIGhh bGYteWVhciBmaW5hbmNp YWwgcmVwb3J0
|
| 2022-07-12 19:26:00 |
RXBpenltZSBJbnZlc3Rv ciBBbGVydCBCeSBUaGUg Rm9ybWVyIEF0dG9ybmV5 IEdlbmVyYWwgT2YgTG91 aXNpYW5hOiBLYWhuIFN3 aWNrICYgRm90aSwgTGxj IEludmVzdGlnYXRlcyBB ZGVxdWFjeSBPZiBQcmlj ZSBBbmQgUHJvY2VzcyBJ biBQcm9wb3NlZCBTYWxl IE9mIEVwaXp5bWUsIElu Yy4gLSBFcHpt
TmV3IG9ybGVhbnMtLShi dXNpbmVzcyB3aXJlKS0t Zm9ybWVyIGF0dG9ybmV5 IGdlbmVyYWwgb2YgbG91 aXNpYW5hIGNoYXJsZXMg Yy4gZm90aSwganIuLCBl c3EuIGFuZCB0aGUgbGF3 IGZpcm0gb2Yga2FobiBz d2ljayAmIGZvdGksIGxs YyAo4oCca3Nm4oCdKSBh cmUgaW52ZXN0aWdhdGlu ZyB0aGUgcHJvcG9zZWQg c2FsZSBvZiBlcGl6eW1l LCBpbmMuIChuYXNkYXFn czogZXB6bSkgdG8gaXBz ZW4gcy5hLiAob3RjOiBp cHNleSkuIHVuZGVyIHRo ZSB0ZXJtcyBvZiB0aGUg cHJvcG9zZWQgdHJhbnNh Y3Rpb24sIHNoYXJlaG9s ZGVycyBvZiBlcGl6eW1l IHdpbGwgcmVjZWl2ZSBv bmx5ICQxLjQ1IGluIGNh c2ggcGx1cyBhIGN2ciAo Y29udGluZ2VudCB2YWx1 ZSByaWdodCkgb2YgJDEu MDAgZm9yIGVhY2ggc2hh cmUgb2YgZXBpenltZSB0 aGF0IHRoZXkgb3duLiBr c2YgaXMgc2Vla2luZyB0 byBkZXRlcm1pbmUgd2hl dGhlciB0aGlzIGNvbnNp ZGVyYXRpb24gYW5kIHRo ZSBwcg==
|
